Existing Patents. On the terms and subject to the conditions set forth herein and subject to rights and licenses granted to third parties on or before the Effective Date, the ownership of all right, title and interest in and to the Existing Patents as of and after the Effective Date shall be apportioned as follows and each party hereto agrees to execute such documents of assignment and to take such other actions as may be required to effect the following:
Existing Patents. (a) All Precision Patents Covering the Licensed Product or the Licensed ARCUS Nuclease that exist as of the Effective Date, other than the Cellectis Patents, that are issued or subject to a pending application for issuance are listed on Exhibit 10.2.2 (the “Existing Patents”).
Existing Patents. (a) All Patent rights contained in the Avidity Technology existing as of the Effective Date that are issued or subject to a pending application for issuance (the “Existing Patents”) are listed on Exhibit 1.14 and all such Existing Patents are: (i) to the extent issued (unless otherwise indicated on Exhibit 1.14), subsisting and not invalid or unenforceable, in whole or in part; (ii) solely and exclusively owned or exclusively licensed to Avidity, free of any encumbrance, lien or claim of ownership by any Third Party; (iii) to the extent subject to a pending application for issuance, being diligently prosecuted in the respective patent offices in which such applications have been filed in accordance with Applicable Law and, to Avidity’s knowledge, Avidity and its Affiliates have presented all relevant references, documents and information to the relevant patent examiner at the relevant patent office; and (iv) to Avidity’s knowledge, filed and maintained properly and correctly, and all applicable fees applicable thereto have been paid on or before the due date for payment.
Existing Patents. [*] [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Existing Patents. Part A The Ablynx Nanobody Patents listed in Schedule 1.12 The Ablynx Product Patents listed in Schedule 1.14 Part B None Schedule 10.2.5 Research Collaboration Agreements […***…]. CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Schedule 10.2.18 Form of Net Sales Disclosure Example Royalty Report ALX-0061 Ablynx Royalty Calculation to their Licensor (“Third Party”) CONFIDENTIAL […***…] […***…] […***…] […***…] CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Schedule 10.2.19 Summary of Material Adverse Information None CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Schedule 11.2.1(vii) Third Party Patents and Intellectual Property Item Country Application Number Application Date [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] Schedule 13.8.2
Existing Patents. Exhibit 10.2(a) attached hereto contains a true and complete list of the existing Licensed Patents as of the Effective Date (the “Existing Patents”);
Existing Patents. Case Reference Country Internal Title Current Status Filing Publication Number Grant Number LEX-1000-AR-NP Argentina SGLT2 Inhibitors Publication of application 28 Sep 2007 AR063047A1 LEX-1000-AT-EPT Austria SGLT2 Inhibitors Grant 27 Sep 2007 2089361 2089361 LEX-1000-AT-ETD Austria SGLT2 Inhibitors Grant 27 Sep 2007 2308841 LEX-1000-AU-PCT Australia SGLT2 Inhibitors Grant 27 Sep 2007 2007304971 LEX-1000-BE-EPT Belgium SGLT2 Inhibitors Grant 27 Sep 2007 2089361 2089361 XXX-0000-XX-XXX Xxxxxxx SGLT2 Inhibitors Grant 27 Sep 2007 2308841 LEX-1000-BR-PCT Brazil SGLT2 Inhibitors Publication of application 27 Sep 2007 2232 LEX-1000-CA-PCT Canada SGLT2 Inhibitors Grant 27 Sep 2007 2,664,688 LEX-1000-CH-EPT Switzerland SGLT2 Inhibitors Grant 27 Sep 2007 2089361 2089361 LEX-1000-CH-ETD Switzerland SGLT2 Inhibitors Grant 27 Sep 2007 2308841 LEX-1000-CN-DIV China SGLT2 Inhibitors Publication of application 14 Mar 2013 CN 103254119A LEX-1000-CN-NP China SGLT2 Inhibitors Grant 02 Apr 2008 CN101343296A ZL200810090073.9 LEX-1000-CZ-EPT Czech Republic SGLT2 Inhibitors Grant 27 Sep 2007 2089361 2089361 LEX-1000-CZ-ETD Czech Republic SGLT2 Inhibitors Grant 27 Sep 2007 2308841 LEX-1000-DE-EPT Germany SGLT2 Inhibitors Grant 27 Sep 2007 2089361 602007012292.9 LEX-1000-DE-ETD Germany SGLT2 Inhibitors Grant 27 Sep 2007 2308841 LEX-1000-DK-EPT Denmark SGLT2 Inhibitors Grant 27 Sep 2007 2089361 2089361 LEX-1000-DK-ETD Denmark SGLT2 Inhibitors Grant 27 Sep 2007 2308841 LEX-1000-EA-EAT Eurasian Procedure SGLT2 Inhibitors Grant 27 Sep 2007 016511 LEX-1000-EP-EPT European Procedure (Patents) SGLT2 Inhibitors Grant 27 Sep 2007 2089361 2089361 LEX-1000-EP-ETD European Procedure (Patents) SGLT2 Inhibitors Grant 27 Sep 2007 2308841 2308841 LEX-1000-ES-EPT Spain SGLT2 Inhibitors Grant 27 Sep 2007 2089361 2089361 LEX-1000-ES-ETD Spain SGLT2 Inhibitors Grant 27 Sep 2007 2308841 LEX-1000-FR-EPT France SGLT2 Inhibitors Grant 27 Sep 2007 2089361 2089361 XXX-0000-XX-XXX Xxxxxx SGLT2 Inhibitors Grant 27 Sep 2007 2308841 LEX-1000-GB-EPT United Kingdom SGLT2 Inhibitors Grant 27 Sep 2007 2089361 2089361 XXX-0000-XX-XXX Xxxxxx Xxxxxxx XXXX0 Inhibitors Grant 27 Sep 2007 2308841 LEX-1000-GR-EPT Greece SGLT2 Inhibitors Grant 27 Sep 2007 2089361 3074740 LEX-1000-GR-ETD Greece SGLT2 Inhibitors Grant 27 Sep 2007 3083670 LEX-1000-HK-FPD Hong Kong SGLT2 Inhibitors Publication of application 04 Sep 2013 1183020A LEX-1000-HK-FPR Hong Kong SGLT2 Inhibitors Grant 19 Mar 2009 1124863A HK1124863 LEX-1000-HU-EPT Hun...
Existing Patents. [***] Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission.
Existing Patents. On the terms and subject to the conditions set forth herein and subject to rights and licenses granted to third parties on or before the Effective Date, GENUITY hereby grants to GTE a worldwide, nonexclusive, perpetual, royalty-free and irrevocable right and license to exercise and otherwise exploit all of the Existing Patents listed on Schedule 2.3A (including, without limitation, the right to make, have made, use, offer for sale, sell, lease and license and to practice any method in the exercise of the foregoing), by any manner and means now known or hereafter devised. This License shall include the right of GTE to sublicense GTE's Affiliates and BCT.Telus Communications Inc. and their successors and assigns; provided, however, that they agree to be bound by the terms and conditions of this Agreement, but shall not otherwise include the right to sublicense.
Existing Patents. On the terms and subject to the conditions set forth herein and subject to rights and licenses granted to third parties on or before the Effective Date, GTE hereby grants to GENUITY a worldwide, nonexclusive, perpetual, royalty-free and irrevocable right and license to exercise and otherwise exploit all Existing Patents solely owned by GTE or its Affiliates as of the Effective Date (i.e., Existing Patents other than those listed on Schedules 2.3A and 2.3B), including, without limitation, the right to make, have made, use, offer for sale, sell, lease and license and to practice any method in the exercise of the foregoing, by any manner and means now known or hereafter devised. This License shall include the right of GENUITY to sublicense GENUITY's Affiliates; provided, however, that they agree to be bound by the terms and conditions of this Agreement, but shall not otherwise include the right to sublicense.
